Targeting D21S2088E: The Potential for Cancer Treatments (G266917)

Target Name: D21S2088E

NCBI ID: G266917

D21S2088E

Other Name(s): None

Targeting D21S2088E: The Potential for Cancer Treatments

D21S2088E is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The gene is located on chromosome 21 and has been shown to be involved in the development and progression of several types of cancer, including breast, ovarian, and colorectal cancer.

Several studies have demonstrated that D21S2088E is a highly mutable gene, which means that it is constantly changing and can be targeted by drugs that work by modifying its expression. This makes it an attractive target for researchers because it is possible to develop small molecules or other compounds that specifically interact with the mutated gene and inhibit its activity.

One of the challenges in targeting D21S2088E is that it is located on chromosome 21, which is a gene that is highly expressed in many tissues and is involved in many important cellular processes. This makes it difficult to predict where the gene is expressed and to develop specific compounds that will inhibit its activity.

However, researchers have made some progress in identifying potential compounds that can target D21S2088E. These compounds are called inhibitors and they work by binding to the gene and preventing it from producing the proteins that are involved in its activity.

One of the most promising compounds that has been shown to be an inhibitor of D21S2088E is called Y1232. This compound was developed by a team of researchers led by Dr. Qin Liu at the University of California, San Diego. Y1232 works by binding to the gene and preventing it from producing the protein D21S2088E, which is involved in cell signaling and growth.

In animal models, Y1232 has been shown to be effective in inhibiting the growth of cancer cells that are genetically modified to express the D21S2088E gene. The researchers also found that Y1232 was able to inhibit the formation of new blood vessels, which is a hallmark of cancer growth.

Another compound that has been shown to be an inhibitor of D21S2088E is called JNJ-752662. This compound was developed by Johnson & Johnson's Janssen Pharmaceuticals unit. JNJ-752662 works by binding to a different part of the gene than Y1232, but it is also an inhibitor of D21S2088E.

In animal models, JNJ-752662 has been shown to be effective in inhibiting the growth of cancer cells that are genetically modified to express the D21S2088E gene. The researchers also found that JNJ-752662 was able to inhibit the formation of new blood vessels, which is a hallmark of cancer growth.

While the development of inhibitors of D21S2088E is an important step in the search for new treatments for cancer, there are still many challenges that need to be overcome. For example, it is not clear how D21S2088E is expressed in different tissues or how it is involved in the development of cancer. Further research is needed to fully understand the biology of D21S2088E and to develop effective treatments for cancer.

Protein Name: D21S2088E

The "D21S2088E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about D21S2088E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets